BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 35624337)

  • 1. Dysregulation and therapeutic targeting of RNA splicing in cancer.
    Stanley RF; Abdel-Wahab O
    Nat Cancer; 2022 May; 3(5):536-546. PubMed ID: 35624337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aberrant RNA splicing and therapeutic opportunities in cancers.
    Yamauchi H; Nishimura K; Yoshimi A
    Cancer Sci; 2022 Feb; 113(2):373-381. PubMed ID: 34812550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic Targeting of RNA Splicing in Cancer.
    Bonner EA; Lee SC
    Genes (Basel); 2023 Jun; 14(7):. PubMed ID: 37510283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RNA Splicing and Cancer.
    Wang E; Aifantis I
    Trends Cancer; 2020 Aug; 6(8):631-644. PubMed ID: 32434734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes.
    Sveen A; Kilpinen S; Ruusulehto A; Lothe RA; Skotheim RI
    Oncogene; 2016 May; 35(19):2413-27. PubMed ID: 26300000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic targeting of splicing in cancer.
    Lee SC; Abdel-Wahab O
    Nat Med; 2016 Sep; 22(9):976-86. PubMed ID: 27603132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting splicing factors for cancer therapy.
    Bashari A; Siegfried Z; Karni R
    RNA; 2023 Apr; 29(4):506-515. PubMed ID: 36697261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pan-cancer analysis identifies mutations in
    Liu Z; Zhang J; Sun Y; Perea-Chamblee TE; Manley JL; Rabadan R
    Proc Natl Acad Sci U S A; 2020 May; 117(19):10305-10312. PubMed ID: 32332164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Splicing dysregulation in cancer: from mechanistic understanding to a new class of therapeutic targets.
    Wang Y; Bao Y; Zhang S; Wang Z
    Sci China Life Sci; 2020 Apr; 63(4):469-484. PubMed ID: 32086672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of the aberrant splicing of MAP3K7 induced by cancer-associated SF3B1 mutation.
    Li Z; Zhao B; Shi Y; Liang Y; Qian R; Wan Y
    J Biochem; 2021 Sep; 170(1):69-77. PubMed ID: 33751071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer-associated SF3B1 mutants recognize otherwise inaccessible cryptic 3' splice sites within RNA secondary structures.
    Kesarwani AK; Ramirez O; Gupta AK; Yang X; Murthy T; Minella AC; Pillai MM
    Oncogene; 2017 Feb; 36(8):1123-1133. PubMed ID: 27524419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of alternative splicing in cancer: From oncogenesis to drug resistance.
    Sciarrillo R; Wojtuszkiewicz A; Assaraf YG; Jansen G; Kaspers GJL; Giovannetti E; Cloos J
    Drug Resist Updat; 2020 Dec; 53():100728. PubMed ID: 33070093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting splicing abnormalities in cancer.
    Agrawal AA; Yu L; Smith PG; Buonamici S
    Curr Opin Genet Dev; 2018 Feb; 48():67-74. PubMed ID: 29136527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Splicing Dysregulation as Oncogenic Driver and Passenger Factor in Brain Tumors.
    Bielli P; Pagliarini V; Pieraccioli M; Caggiano C; Sette C
    Cells; 2019 Dec; 9(1):. PubMed ID: 31861467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of SF3B1 by molecules targeting the spliceosome results in massive aberrant exon skipping.
    Wu G; Fan L; Edmonson MN; Shaw T; Boggs K; Easton J; Rusch MC; Webb TR; Zhang J; Potter PM
    RNA; 2018 Aug; 24(8):1056-1066. PubMed ID: 29844105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multilayered control of splicing regulatory networks by DAP3 leads to widespread alternative splicing changes in cancer.
    Han J; An O; Ren X; Song Y; Tang SJ; Shen H; Ke X; Ng VHE; Tay DJT; Tan HQ; Kappei D; Yang H; Chen L
    Nat Commun; 2022 Apr; 13(1):1793. PubMed ID: 35379802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types.
    Seiler M; Peng S; Agrawal AA; Palacino J; Teng T; Zhu P; Smith PG; ; Buonamici S; Yu L
    Cell Rep; 2018 Apr; 23(1):282-296.e4. PubMed ID: 29617667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SnapShot: Splicing Alterations in Cancer.
    Rahman MA; Krainer AR; Abdel-Wahab O
    Cell; 2020 Jan; 180(1):208-208.e1. PubMed ID: 31951519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging roles of spliceosome in cancer and immunity.
    Yang H; Beutler B; Zhang D
    Protein Cell; 2022 Aug; 13(8):559-579. PubMed ID: 34196950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SF3B2-Mediated RNA Splicing Drives Human Prostate Cancer Progression.
    Kawamura N; Nimura K; Saga K; Ishibashi A; Kitamura K; Nagano H; Yoshikawa Y; Ishida K; Nonomura N; Arisawa M; Luo J; Kaneda Y
    Cancer Res; 2019 Oct; 79(20):5204-5217. PubMed ID: 31431456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.